Skip to main content
SpringerLink
Log in

Molecular Markers for Patient Selection and Stratification: Personalized Prognostic Predictive Models

  • Chapter
  • First Online:
Prostate Cancer: Shifting from Morphology to Biology

  • 1146 Accesses

Abstract

The emerging data from US statistics on prostate cancer screening (Carlsson et al., J Clin Oncol 30(21):2581–2584, 2012; Brawley, Ann Intern Med 157(2):135–136, 2012) and the early results of the 11-year follow-up European Randomized Study of Screening for Prostate Cancer (ERSPC) involving eight countries (Belgium, Finland, France, Italy, Netherlands, Spain, Sweden and Switzerland), have evidenced that the main downside to large-scale PSA screening is over-diagnosis of biologically “indolent” cancers. They constitute about 30 % of detected cancers, and cause the facing of patients with the side effects of unnecessary treatment. Currently, the only way for men suffering for these “biologically insignificant” prostate cancers to delay unnecessary therapies is to offer them an Active Surveillance programme based upon regular check-up schedules.

It seems evident that there is an urgent need to find new reliable molecular markers able to predict the biological aggressiveness of each case of prostate cancer, in order to (Hamburg and Collins, N Engl J Med 363(11):1092, 2010) warrant the successful establishment and performance of personalized medicine. This, in turn, necessitate of substantial investments in infrastructure and standards, which may hasten a thorough understanding of the genetic basis of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aggarwal R, Ryan CJ (2011) Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 16(3):264–275

    Article  PubMed  CAS  Google Scholar 

  • Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS et al (2001) A novel mechanism for Chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 61:4791–4796

    PubMed  CAS  Google Scholar 

  • Alix-Panabières C (2012) EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 195:69–76

    Article  PubMed  Google Scholar 

  • Brawley OW (2012) Prostate cancer screening: what we know, don’t know, and believe. Ann Intern Med 157(2):135–136

    Article  PubMed  Google Scholar 

  • Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106(4):768–774

    Article  PubMed  CAS  Google Scholar 

  • Cairns P et al (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7:2727–2730

    PubMed  CAS  Google Scholar 

  • Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J (2012) Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force review. J Clin Oncol 30(21):2581–2584

    Article  PubMed  Google Scholar 

  • Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N, Hall P, Pharoah P, Burton H (2013) Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med 15(6):423–32, Epub 2013 Feb 14

    Article  PubMed  CAS  Google Scholar 

  • Delacruz A (2012) Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer. Clin J Oncol Nurs 16(2):E44–E47

    Article  PubMed  Google Scholar 

  • Duijvesz D, Luider T, Bangma CH, Jenster G (2011) Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 59(5):823–831

    Article  PubMed  CAS  Google Scholar 

  • Fernandez AF et al (2011) A DNA methylation fingerprint of 1628 human samples. Genome Res 22:407–419

    Article  PubMed  Google Scholar 

  • Fu W, Madan E, Yee M, Zhang H (2012) Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta 1825(2):140–152

    PubMed  CAS  Google Scholar 

  • Gimba ER, Barcinski MA (2003) Molecular aspects of prostate cancer: implications for future directions. Int Braz J Urol 29(5):401–410, discussion 411

    Article  PubMed  Google Scholar 

  • Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363(4):301–304, Epub 2010 Jun 15. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092

    Article  PubMed  CAS  Google Scholar 

  • Hanin L (2013) Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment. Adv Exp Med Biol 734:261–282

    Article  PubMed  Google Scholar 

  • Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM (2007) Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 6(5):1629–1640

    Article  PubMed  CAS  Google Scholar 

  • Jadvar H (2009) FDG PET, in prostate cancer. PET Clin 4(2):155–161

    Article  PubMed  Google Scholar 

  • Kattan MW, Stapleton AM, Wheeler TM et al (1997) Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79:528–537

    Article  PubMed  CAS  Google Scholar 

  • Kattan MW, Eastham JA, Stapleton AMF et al (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766–771

    Article  PubMed  CAS  Google Scholar 

  • Kattan MW, Zelefsky MJ, Kupelian PA et al (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352–3359

    PubMed  CAS  Google Scholar 

  • Kattan MW, Potters L, Blasko JC et al (2001) Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58:393–399

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Hegde P, Zhang F, Hampton G, Jia S (2012) Prostate cancer – a biomarker perspective. Front Endocrinol (Lausanne) 3:72

    CAS  Google Scholar 

  • Lofton-Day C et al (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54:414–423

    Article  PubMed  CAS  Google Scholar 

  • Merino M, Pinto A, González R, Espinosa E (2011) Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer 47(12):1846–1851

    Article  PubMed  CAS  Google Scholar 

  • Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30):10513–10518

    Article  PubMed  CAS  Google Scholar 

  • Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H (2011) Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem 22(8):1700–1705

    Article  PubMed  CAS  Google Scholar 

  • Nanni S, Narduci M, Pietra LD, Moretti F, Grasselli A, De Carli O et al (2002) Siganling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 11:219–227

    Google Scholar 

  • Partin AW, Yoo J, Carter HB et al (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110–114

    PubMed  CAS  Google Scholar 

  • Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58:843–848

    Article  PubMed  CAS  Google Scholar 

  • Roberts MJ, Schirra HJ, Lavin MF, Gardiner RA (2011) Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol 52(2):79–89

    Article  PubMed  Google Scholar 

  • Rosenbaum E et al (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11:8321–8325

    Article  PubMed  CAS  Google Scholar 

  • Schroten C, Dits NF, Steyerberg EW, Kranse R, van Leenders AG, Bangma CH, Kraaij R (2012) The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Cancer Immunol Immunother 61(6):905–910

    Article  PubMed  CAS  Google Scholar 

  • Spratlin JL, Serkova NJ, Eckhardt SG (2009) Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15(2):431–440

    Article  PubMed  CAS  Google Scholar 

  • Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910–914

    Article  PubMed  CAS  Google Scholar 

  • Szász AM, Nyirády P, Majoros A, Szendrõi A, Szûcs M, Székely E, Tõkés AM, Romics I, Kulka J (2010) Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 105(5):716–722

    Article  PubMed  Google Scholar 

  • Tavazoie SF, Alarcon C, Oskars-son T, Padua D, Wang Q, Bos PD, Gerald WL, Mas-sague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147–152

    Article  PubMed  CAS  Google Scholar 

  • Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J (2008) Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 60(3):510–516

    Article  PubMed  CAS  Google Scholar 

  • Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM (2011) Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):94ra72

    Article  PubMed  CAS  Google Scholar 

  • Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659

    Article  PubMed  CAS  Google Scholar 

  • Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71(3):326–331

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Advanced Biomedical Sciences, Pathology Section, Faculty of Medicine and Surgery, University of Naples “Federico II”, via S. Pansini, n.5, 80131, Naples, Italy

    Stefania Staibano

Authors
  1. Stefania Staibano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefania Staibano .

Editor information

Editors and Affiliations

  1. Biomedical Advanced Sciences Pathology Section, University Federico II of Naples, Naples, Italy

    Stefania Staibano

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Staibano, S. (2013). Molecular Markers for Patient Selection and Stratification: Personalized Prognostic Predictive Models. In: Staibano, S. (eds) Prostate Cancer: Shifting from Morphology to Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7149-9_13

Download citation

Publish with us

Policies and ethics

Search

Navigation